Systemic lupus erythematosus (SLE) is a complex autoimmune disease in which the immune system generates antibodies that attack the body's own tissues, affecting the joints, skin, kidneys, heart, lungs, and nervous system. For patients with moderate-to-severe lupus that is inadequately controlled by conventional medications, IV biologic therapies offer a targeted approach to disease management.
For many lupus patients on stable biologic therapy, receiving these infusions through
home infusion therapy is a clinically appropriate alternative to repeated infusion center visits.
Pharmko coordinates lupus biologic infusions for patients and rheumatologists across 22+ states.
IV Biologic Therapies Used in Lupus
Benlysta (belimumab)
Benlysta is a monoclonal antibody that targets BLyS (B lymphocyte stimulator), a protein that supports the survival of autoreactive B cells, cells that produce the antibodies driving lupus inflammation and organ damage. By blocking BLyS, Benlysta reduces the number and activity of these harmful B cells, lowering disease activity and reducing flare frequency.
Benlysta is FDA-approved for active, autoantibody-positive SLE in adults and for active lupus nephritis. It is available in two formulations: IV infusion (given monthly after loading doses at weeks 0, 2, and 4) and subcutaneous injection (given weekly). The IV formulation is administered over one hour and is the standard route for patients initiating therapy or who prefer monthly dosing over weekly self-injection.
Saphnelo (anifrolumab)
Saphnelo is a newer IV biologic approved in 2021 for moderate-to-severe SLE in adults on standard therapy. It blocks the type I interferon receptor, a signaling pathway overactivated in many lupus patients and associated with disease flares and organ damage. Saphnelo is administered by IV infusion every 4 weeks over 30 minutes.
Because Saphnelo is relatively new, fewer patients have transitioned to home infusion compared to Benlysta, but it is appropriate for home administration in stable patients following the same criteria as other IV biologics.
IVIG in Lupus
Intravenous immunoglobulin (IVIG) is used off-label in certain severe manifestations of lupus, including thrombocytopenia, hemolytic anemia, and neuropsychiatric lupus, typically as a bridge therapy or when conventional immunosuppressants are contraindicated. It is not a first-line treatment for SLE but plays a role in acute flare management.
Who Qualifies for Home Infusion of Lupus Biologics?
Home infusion of IV lupus biologics is appropriate for patients who:
- Have received their initial loading doses (weeks 0, 2, and 4 for Benlysta) in a supervised clinical setting without significant infusion reactions
- Are on a stable, maintenance dosing schedule
- Have been assessed by their rheumatologist as clinically stable for home-based administration
- Have lupus nephritis or other organ involvement that is being actively monitored but does not require inpatient care
Patients with active lupus flares, new organ involvement, or recent serious infections typically require physician-supervised infusions until their clinical situation is stabilized.
What to Expect During a Home Lupus Infusion
Before the infusion
A Pharmko nurse reviews your current medications, confirms the absence of active infection, checks vital signs, and prepares the medication. Pre-medications may be administered per your rheumatologist's orders.
During the infusion
Benlysta infusions run over one hour; Saphnelo over 30 minutes. Your nurse monitors your vital signs throughout and is present to respond to any reaction. The infusion rate may be slowed if you experience nausea, headache, or other mild symptoms.
After the infusion
Your nurse documents the session and communicates with your rheumatologist's office. Know
which symptoms require an immediate call in the hours following your infusion, including fever, chest tightness, or new joint swelling, and save our
after-hours support number before your first home dose.
Lupus and the Broader Autoimmune Infusion Landscape
Lupus patients may also have overlapping conditions, particularly Sjögren's syndrome, antiphospholipid syndrome, or lupus nephritis, that introduce additional treatment considerations. For patients managing multiple autoimmune conditions treated with IV biologics, our guide on
home infusion for autoimmune diseases provides a broader overview of how these therapies are coordinated. For Crohn's disease specifically, which shares some biologic treatment pathways, see our guide on
home infusion for Crohn's disease.
Insurance Coverage for Lupus Biologic Infusions
Benlysta and Saphnelo are covered under the medical benefit by Medicare Part B and most commercial insurance plans when administered by a licensed provider to patients with documented active, autoantibody-positive SLE. Prior authorization is required and must include lab documentation of autoantibody positivity and evidence of inadequate response to standard therapy.
Pharmko manages the full authorization process and communicates any coverage issues before your first home infusion.
→
Contact Pharmko to start a lupus infusion referral:
1-877-540-2003
